Fred Hutchinson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fred Hutchinson Cancer Center sits in the top decile of US sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count).
Fred Hutchinson Cancer Center: 483 sponsored US clinical trials, 57 recruiting.
Fred Hutchinson Cancer Center sponsors 483 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 327 completed. 27 of these trials are in Phase 3-4 (later-stage) and 304 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 10 trials.
Top-decile sponsor footprint
Fred Hutchinson Cancer Center ranks in the top decile of sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
327 of 391 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
483 total, page 1 of 10
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07194980
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
NCT07490860
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
NCT07094750
A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
NCT06909500
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT07535008
A Novel Mobile Health Intervention for Improving Tobacco Cessation Among Young Adults
NCT07571018
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
NCT07225985
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
NCT07141407
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
NCT07181941
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NCT07282158
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NCT06802172
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
NCT07228624
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
NCT06983899
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
NCT07209371
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
NCT07227571
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
NCT07098364
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
NCT06817889
A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial
NCT06822530
Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education
NCT06995924
Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial
NCT07052630
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
NCT07046078
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
NCT06752694
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
NCT06928662
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
NCT07011810
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
NCT05835154
Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
NCT05930496
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
NCT06145763
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
NCT06839053
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
NCT05930483
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
NCT06922188
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT06609928
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
NCT04515810
Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
NCT05067595
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06236139
Cooking for Your Health in Southern New Mexico: an 8-week, Bilingual (English and Spanish) Nutritional Intervention in Adults Living in Doña Ana and Otero Counties
NCT06609057
DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial
NCT06492707
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
NCT06145633
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT06013423
IVIG for Infection Prevention After CAR-T-Cell Therapy
NCT05952804
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
NCT06034470
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
NCT06043713
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
NCT05996627
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
NCT04941716
Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies
NCT04829136
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
NCT05250037
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
NCT03980769
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
NCT04370301
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
NCT04195633
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
NCT04375631
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 144 |
| Phase 2 | 160 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Fred Hutchinson Cancer Center pipeline
57 recruiting of 483 indexed (12% open); 327 completed (68%).
Phase mix: 27 late (III/IV) vs 304 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fred Hutchinson Cancer Center: open-pipeline peers nationwide
Peers matched on 483 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Fred Hutchinson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 483 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Fred Hutchinson Cancer Center page
483 registered trials is a research-attention snapshot, not an endorsement of Fred Hutchinson Cancer Center or any single study.
- 57 of Fred Hutchinson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Fred Hutchinson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fred Hutchinson Cancer Center pipeline card: 483 registered trials from official public datasets.Report a data error.